Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pevonedistat with Induction Chemotherapy in AYA Relapsed/Refractory ALL or Lymphoblastic Lymphoma
NCT03349281Phase 1Completed
- Start
- Mar 2019
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of pevonedistat in acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LL) (3 arms). Primary endpoints: Rate of Toxicity in Study Participants Receiving Protocol Therapy up to 90 days and Maximum Tolerated Dose up to 90 days. Started Mar 2019; status: completed.
02
Drugs
pevonedistat
03
Conditions
acute lymphoblastic leukemia (ALL)lymphoblastic lymphoma (LL)
Beyond the preview
Go deeper on NCT03349281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03349281.